Posted Feb. 1, 2016 at 3:27 p.m.
RESEARCH TRIANGLE PARK, N.C. — Zoion Pharma of Durham has formed a collaboration with the French veterinary company Ceva Santé Animale to develop a treatment for eye diseases in companion animals.
The companies did not disclose financial terms of the collaboration which gives Ceva worldwide development and commercial rights to Zoion’s drug candidate ZP-1, which Zoion has been targeting as a dry-eye treatment for dogs.
Technically, it’s an epithelial sodium channel inhibitor for the treatment of veterinary ocular surface diseases involving a lack of surface hydration, such as keratoconjunctivitis sicca (KCS), commonly called dry eye.
“KCS is a disease that causes much pain and discomfort, particularly in dogs,” said Jon Alšėnas, D.V.M., president and CEO of Zoion. “If left untreated, severe cases may lead to blindness.”
Drug originally discovered by Parion Sciences
ZP-1 has successfully completed a proof-of-concept clinical trial in canine dry eye. It was originally discovered by Parion Sciences of Durham and then licensed to Zoion for veterinary use. [Read full article….]